Phase II trial of SOM230 in patients with unresectable hepatocellular carcinoma (HCC).

e15588Background: Standard therapy for unresectable HCC is sorafenib which is poorly tolerated by some patients (pts) with modest benefit in disease control rate (DCR). There is no established seco...